cyclosporine · Harrow Eye · NDA 217469
Vevye
Earliest generic entry, as listed
1 Apr 2042
Blocked by patent: US 12059449.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12059449 | product, use U-1483 | 1 Apr 2042 |
| US 11413323 | use U-3627 | 11 Oct 2039 |
| US 10813976 | product | 22 Sep 2037 |
| US 12496326 | use U-3627 | 29 Sep 2036 |
| US 8614178 | product | 13 Dec 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217469 · 001 · RLD | solution, ophthalmic | 0.1% | 1 Apr 2042 |
Expired or delisted (1)
- NP · 30 May 2026